JP2013507131A - Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 - Google Patents
Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 Download PDFInfo
- Publication number
- JP2013507131A JP2013507131A JP2012533375A JP2012533375A JP2013507131A JP 2013507131 A JP2013507131 A JP 2013507131A JP 2012533375 A JP2012533375 A JP 2012533375A JP 2012533375 A JP2012533375 A JP 2012533375A JP 2013507131 A JP2013507131 A JP 2013507131A
- Authority
- JP
- Japan
- Prior art keywords
- ids
- amino acid
- fusion antibody
- activity
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 106
- 230000000694 effects Effects 0.000 title claims description 197
- 239000000203 mixture Substances 0.000 title abstract description 74
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 title abstract description 10
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 title abstract description 8
- 230000004927 fusion Effects 0.000 claims abstract description 216
- 230000008499 blood brain barrier function Effects 0.000 claims abstract description 159
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 159
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 42
- 238000007910 systemic administration Methods 0.000 claims abstract description 13
- 230000007812 deficiency Effects 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 138
- 108020001507 fusion proteins Proteins 0.000 claims description 115
- 102000037865 fusion proteins Human genes 0.000 claims description 114
- 210000004556 brain Anatomy 0.000 claims description 78
- 210000004027 cell Anatomy 0.000 claims description 62
- 102000005962 receptors Human genes 0.000 claims description 51
- 108020003175 receptors Proteins 0.000 claims description 51
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 42
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 42
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 41
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 41
- 210000004899 c-terminal region Anatomy 0.000 claims description 34
- 102000003746 Insulin Receptor Human genes 0.000 claims description 32
- 108010001127 Insulin Receptor Proteins 0.000 claims description 32
- 108060003951 Immunoglobulin Proteins 0.000 claims description 27
- 102000018358 immunoglobulin Human genes 0.000 claims description 27
- 230000001404 mediated effect Effects 0.000 claims description 25
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims description 23
- 230000037396 body weight Effects 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 claims description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 13
- 229920002971 Heparan sulfate Polymers 0.000 claims description 13
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 claims description 13
- 102000005262 Sulfatase Human genes 0.000 claims description 13
- 108060007951 sulfatase Proteins 0.000 claims description 13
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 10
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 10
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 10
- 229940051593 dermatan sulfate Drugs 0.000 claims description 10
- 230000007062 hydrolysis Effects 0.000 claims description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 239000003607 modifier Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 235000018417 cysteine Nutrition 0.000 claims description 8
- 229920000669 heparin Polymers 0.000 claims description 8
- 229960002897 heparin Drugs 0.000 claims description 8
- 238000007918 intramuscular administration Methods 0.000 claims description 8
- 238000007920 subcutaneous administration Methods 0.000 claims description 8
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 6
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 102000005861 leptin receptors Human genes 0.000 claims description 6
- 108010019813 leptin receptors Proteins 0.000 claims description 6
- 230000004481 post-translational protein modification Effects 0.000 claims description 6
- 241000699802 Cricetulus griseus Species 0.000 claims description 5
- 102000011965 Lipoprotein Receptors Human genes 0.000 claims description 5
- 108010061306 Lipoprotein Receptors Proteins 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 238000001361 intraarterial administration Methods 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 108010003381 Iduronidase Proteins 0.000 claims description 2
- 102000004627 Iduronidase Human genes 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 230000001588 bifunctional effect Effects 0.000 abstract description 9
- 235000001014 amino acid Nutrition 0.000 description 134
- 229940024606 amino acid Drugs 0.000 description 120
- 150000001413 amino acids Chemical class 0.000 description 91
- 108090000623 proteins and genes Proteins 0.000 description 82
- 235000018102 proteins Nutrition 0.000 description 68
- 102000004169 proteins and genes Human genes 0.000 description 68
- 241000282414 Homo sapiens Species 0.000 description 62
- 229940088598 enzyme Drugs 0.000 description 61
- 102000004190 Enzymes Human genes 0.000 description 60
- 108090000790 Enzymes Proteins 0.000 description 58
- 125000005647 linker group Chemical group 0.000 description 50
- 102100026031 Beta-glucuronidase Human genes 0.000 description 43
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 43
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 42
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 33
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 230000032258 transport Effects 0.000 description 28
- 239000000427 antigen Substances 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 24
- 230000035772 mutation Effects 0.000 description 24
- 108010076504 Protein Sorting Signals Proteins 0.000 description 23
- 238000006467 substitution reaction Methods 0.000 description 23
- 201000002273 mucopolysaccharidosis II Diseases 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 20
- 210000002950 fibroblast Anatomy 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 18
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 18
- 102000047882 human INSR Human genes 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 230000009885 systemic effect Effects 0.000 description 17
- 101000840540 Homo sapiens Iduronate 2-sulfatase Proteins 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 102000057422 human IDS Human genes 0.000 description 15
- 108010078791 Carrier Proteins Proteins 0.000 description 14
- 229920002683 Glycosaminoglycan Polymers 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 13
- 101100437500 Homo sapiens GUSB gene Proteins 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 11
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 11
- 239000013613 expression plasmid Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 239000004471 Glycine Substances 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 230000035508 accumulation Effects 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000002641 enzyme replacement therapy Methods 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 238000001712 DNA sequencing Methods 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003636 conditioned culture medium Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- -1 recombinant proteins Chemical class 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 101150074155 DHFR gene Proteins 0.000 description 5
- 108010022394 Threonine synthase Proteins 0.000 description 5
- 108090000901 Transferrin Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 102000004419 dihydrofolate reductase Human genes 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000007421 fluorometric assay Methods 0.000 description 5
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000002132 lysosomal effect Effects 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 102000016267 Leptin Human genes 0.000 description 4
- 108010092277 Leptin Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000000185 intracerebroventricular administration Methods 0.000 description 4
- 229940039781 leptin Drugs 0.000 description 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 3
- PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical group C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 description 3
- 102100035028 Alpha-L-iduronidase Human genes 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 3
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 101150027568 LC gene Proteins 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002457 bidirectional effect Effects 0.000 description 3
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000007923 nasal drop Substances 0.000 description 3
- 229940100662 nasal drops Drugs 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100028146 F-box/WD repeat-containing protein 2 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101001060245 Homo sapiens F-box/WD repeat-containing protein 2 Proteins 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 108010072166 idursulfase Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000007981 phosphate-citrate buffer Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- PURMPUDWXOWORS-SKNVOMKLSA-N (2r,3s,4s,5r)-2,3,4-trihydroxy-6-oxo-5-sulfooxyhexanoic acid Chemical group OC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](OS(O)(=O)=O)C=O PURMPUDWXOWORS-SKNVOMKLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- JUAGNSFMKLTCCT-UHFFFAOYSA-N 2-aminoacetic acid;carbonic acid Chemical compound OC(O)=O.NCC(O)=O JUAGNSFMKLTCCT-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000648617 Homo sapiens Inactive C-alpha-formylglycine-generating enzyme 2 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102100028867 Inactive C-alpha-formylglycine-generating enzyme 2 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- OXFPUTVGMDTUNO-SKNVOMKLSA-N L-iduronic acid 2-sulfate Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)OS(O)(=O)=O OXFPUTVGMDTUNO-SKNVOMKLSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 1
- 208000028781 Mucopolysaccharidosis type 1 Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 201000001828 Sly syndrome Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- YVXXRFJXBIWXFT-UHFFFAOYSA-N [1-hydroxy-2-(hydroxymethyl)butan-2-yl]azanium;(4-nitrophenyl) phosphate Chemical compound CCC(N)(CO)CO.CCC(N)(CO)CO.OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 YVXXRFJXBIWXFT-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 229940022705 aldurazyme Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000004858 capillary barrier Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940012882 elaprase Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000002824 mRNA display Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000012253 mucopolysaccharidosis IVA Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007331 pathological accumulation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000012036 ultra high throughput screening Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25037809P | 2009-10-09 | 2009-10-09 | |
| US61/250,378 | 2009-10-09 | ||
| US25604909P | 2009-10-29 | 2009-10-29 | |
| US61/256,049 | 2009-10-29 | ||
| PCT/US2010/052113 WO2011044542A1 (en) | 2009-10-09 | 2010-10-08 | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016014716A Division JP2016155805A (ja) | 2009-10-09 | 2016-01-28 | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507131A true JP2013507131A (ja) | 2013-03-04 |
| JP2013507131A5 JP2013507131A5 (enExample) | 2013-07-25 |
Family
ID=43857180
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533375A Withdrawn JP2013507131A (ja) | 2009-10-09 | 2010-10-08 | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| JP2016014716A Pending JP2016155805A (ja) | 2009-10-09 | 2016-01-28 | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| JP2018089998A Pending JP2018154629A (ja) | 2009-10-09 | 2018-05-08 | Ｃｎｓにおけるイズロン酸 ２−スルファターゼ活性を増加させるための方法および組成物 |
| JP2020167101A Pending JP2021008488A (ja) | 2009-10-09 | 2020-10-01 | Ｃｎｓにおけるイズロン酸 ２−スルファターゼ活性を増加させるための方法および組成物 |
| JP2022205808A Pending JP2023033321A (ja) | 2009-10-09 | 2022-12-22 | Ｃｎｓにおけるイズロン酸 ２－スルファターゼ活性を増加させるための方法および組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016014716A Pending JP2016155805A (ja) | 2009-10-09 | 2016-01-28 | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| JP2018089998A Pending JP2018154629A (ja) | 2009-10-09 | 2018-05-08 | Ｃｎｓにおけるイズロン酸 ２−スルファターゼ活性を増加させるための方法および組成物 |
| JP2020167101A Pending JP2021008488A (ja) | 2009-10-09 | 2020-10-01 | Ｃｎｓにおけるイズロン酸 ２−スルファターゼ活性を増加させるための方法および組成物 |
| JP2022205808A Pending JP2023033321A (ja) | 2009-10-09 | 2022-12-22 | Ｃｎｓにおけるイズロン酸 ２－スルファターゼ活性を増加させるための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US8834874B2 (enExample) |
| EP (3) | EP4273164A3 (enExample) |
| JP (5) | JP2013507131A (enExample) |
| DK (1) | DK2485761T3 (enExample) |
| ES (1) | ES2725200T3 (enExample) |
| HR (1) | HRP20190690T1 (enExample) |
| HU (1) | HUE044865T2 (enExample) |
| PL (1) | PL2485761T3 (enExample) |
| PT (1) | PT2485761T (enExample) |
| SI (1) | SI2485761T1 (enExample) |
| WO (1) | WO2011044542A1 (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015098989A1 (ja) | 2013-12-25 | 2015-07-02 | Ｊｃｒファーマ株式会社 | 血液脳関門を通過する新規抗トランスフェリン受容体抗体 |
| JP2016525545A (ja) * | 2013-07-22 | 2016-08-25 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2016155805A (ja) * | 2009-10-09 | 2016-09-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| WO2018038243A1 (ja) * | 2016-08-25 | 2018-03-01 | Ｊｃｒファーマ株式会社 | 抗体融合蛋白質の製造方法 |
| JP2021533167A (ja) * | 2018-08-07 | 2021-12-02 | アーマジェン・インコーポレイテッドArmagen, Inc. | ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル−タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物 |
| JP2022512575A (ja) * | 2018-10-26 | 2022-02-07 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | Ｉｄｓを含む融合タンパク質及びその使用 |
| JP2022526799A (ja) * | 2019-04-03 | 2022-05-26 | デナリ セラピューティクス インコーポレイテッド | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
| JP2024532176A (ja) * | 2021-08-18 | 2024-09-05 | ジョイント－ストック カンパニー “ジェネリウム” | 療法酵素のターゲティング化送達 |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2496493T3 (es) | 2002-01-11 | 2014-09-19 | Bioasis Technologies Inc. | Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas |
| US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| US8497246B2 (en) | 2006-08-18 | 2013-07-30 | Armagen Technologies, Inc. | Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions |
| EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| JP5873003B2 (ja) | 2009-03-18 | 2016-03-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法 |
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| JP6208658B2 (ja) | 2011-07-05 | 2017-10-04 | バイオアシス テクノロジーズ インコーポレイテッド | ｐ９７−抗体結合体および使用方法 |
| US8486399B2 (en) | 2011-12-02 | 2013-07-16 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| CA2862979A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
| JP6684490B2 (ja) | 2012-01-09 | 2020-04-22 | ザ・スクリップス・リサーチ・インスティテュート | 超長相補性決定領域及びその使用 |
| US9603908B2 (en) | 2012-03-30 | 2017-03-28 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate-2-sulfatase |
| US9150841B2 (en) * | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| US20140004097A1 (en) * | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
| KR101380740B1 (ko) * | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| JP6433424B2 (ja) * | 2012-07-31 | 2018-12-05 | バイオアシス テクノロジーズ インコーポレイテッド | 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法 |
| WO2014082184A1 (en) * | 2012-11-30 | 2014-06-05 | Angiochem Inc. | Targeted iduronate-2-sulfatase compounds |
| US10259863B2 (en) | 2013-01-11 | 2019-04-16 | The California Institute For Biomedical Research | Bovine fusion antibodies |
| CN105263958B (zh) | 2013-03-13 | 2019-09-27 | 比奥阿赛斯技术有限公司 | p97片段及其应用 |
| CN105814074B (zh) | 2013-07-18 | 2020-04-21 | 图鲁斯生物科学有限责任公司 | 具有超长互补决定区的人源化抗体 |
| US20150093399A1 (en) | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| BR112016017933A2 (pt) | 2014-02-03 | 2017-10-10 | Bioasis Technologies Inc | ?proteínas de fusão p97? |
| AU2015219339B2 (en) | 2014-02-19 | 2020-03-05 | Bioasis Technologies Inc. | P97-IDS fusion proteins |
| DK3114141T3 (da) * | 2014-03-06 | 2020-08-10 | Nat Res Council Canada | Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf |
| UA120048C2 (uk) * | 2014-03-06 | 2019-09-25 | Нешнл Рісеч Каунсіл Оф Канада | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) |
| US10100117B2 (en) * | 2014-03-06 | 2018-10-16 | National Research Council Of Canada | Insulin-like growth factor 1 receptor-specific antibodies and uses thereof |
| DE102014205817A1 (de) * | 2014-03-28 | 2015-10-01 | Aktiebolaget Skf | Wälzlagerkäfig und Verfahren zur Montage eines Wälzlagerkäfigs |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| EP3101125A1 (en) * | 2015-06-05 | 2016-12-07 | Laboratorios Del Dr. Esteve, S.A. | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses |
| CN107921143B (zh) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | 用于治疗软脑膜癌病的方法 |
| US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
| KR20250073514A (ko) * | 2015-06-24 | 2025-05-27 | 제이씨알 파마 가부시키가이샤 | 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체 |
| CA2997745A1 (en) | 2015-09-14 | 2017-03-23 | Children's Hospital Medical Center | Methods and compositions for treatment of gaucher disease via modulation of c5a receptor |
| RU2673038C2 (ru) * | 2016-01-18 | 2018-11-21 | ООО "Международный Биотехнологический Центр "Генериум" | Лекарственное средство на основе бифункционального антитела для лечения мукополисахаридоза II типа |
| WO2018124107A1 (ja) | 2016-12-26 | 2018-07-05 | Ｊｃｒファーマ株式会社 | Ｂｄｎｆを含む融合蛋白質 |
| TWI761413B (zh) | 2016-12-26 | 2022-04-21 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| SG11202002730XA (en) | 2017-10-02 | 2020-04-29 | Denali Therapeutics Inc | Fusion proteins comprising enzyme replacement therapy enzymes |
| WO2019143761A1 (en) * | 2018-01-17 | 2019-07-25 | Children's Hospital Medical Center | Compositions and methods for treatment of hunter's syndrome |
| EP3784701A4 (en) * | 2018-04-24 | 2022-06-08 | National Research Council of Canada | THERAPEUTIC COMPOUNDS CROSSING THE BLOOD-BRAIN BARRIER AND THEIR USES |
| WO2020132452A1 (en) * | 2018-12-20 | 2020-06-25 | Shire Human Genetic Therapies, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
| EP3954393A1 (en) | 2020-08-13 | 2022-02-16 | Bioasis Technologies Inc. | Combination therapies for delivery across the blood brain barrier |
| BR112023013864A2 (pt) | 2021-01-12 | 2023-10-03 | Japan Chem Res | Molécula de ácido nucleico, célula, tecido ou animal, célula-tronco, plasmídeo, e, vírion |
| JPWO2023090409A1 (enExample) | 2021-11-19 | 2023-05-25 | ||
| US20250059292A1 (en) | 2021-12-28 | 2025-02-20 | Jcr Pharmaceuticals Co., Ltd. | Fusion Protein of Anti-Transferrin Receptor Antibody and Physiologically Active Protein for Safe Gene Therapy |
| KR20250148614A (ko) | 2023-02-07 | 2025-10-14 | 제이씨알 파마 가부시키가이샤 | 인간 트랜스페린 수용체 친화성 펩타이드 |
| WO2024177535A1 (ru) | 2023-02-21 | 2024-08-29 | Акционерное общество "ГЕНЕРИУМ" | Фармацевтическая композиция и способ профилактики и лечения недостаточности лизосомального фермента у субъекта, имеющего мукополисахаридоз ii типа |
Family Cites Families (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5180820A (en) * | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
| US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
| NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US6329508B1 (en) * | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| EP1132471A3 (de) * | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| TW279133B (enExample) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| US6060069A (en) | 1991-05-20 | 2000-05-09 | Dura Pharmaceuticals, Inc. | Pulmonary delivery of pharmaceuticals |
| US6287792B1 (en) * | 1991-06-17 | 2001-09-11 | The Regents Of The University Of California | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology |
| EP0528767B1 (en) * | 1991-08-21 | 2000-01-12 | Novartis AG | Antibody derivatives |
| ATE275197T1 (de) * | 1991-09-20 | 2004-09-15 | Amgen Inc | Glial neurotrophe faktor |
| JPH06228199A (ja) | 1992-11-27 | 1994-08-16 | Takeda Chem Ind Ltd | 血液脳関門通過可能なペプチド結合体 |
| CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
| US6195608B1 (en) | 1993-05-28 | 2001-02-27 | Lucent Technologies Inc. | Acoustic highway monitor |
| US5997501A (en) | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
| ATE208633T1 (de) * | 1994-09-16 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| US5656284A (en) * | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
| AU6163196A (en) * | 1995-06-07 | 1996-12-30 | Smithkline Beecham Corporation | Method for obtaining receptor agonist antibodies |
| AU719613B2 (en) | 1995-09-19 | 2000-05-11 | Astellas Pharma Inc. | Aerosol compositions |
| US6015662A (en) * | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
| US5837231A (en) * | 1996-06-27 | 1998-11-17 | Regents Of The University Of Minnesota | GM-CSF administration for the treatment and prevention of recurrence of brain tumors |
| CA2261032C (en) | 1996-07-16 | 2003-11-25 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Dibenzodihydropyridinecarboxylic esters and their use in chemiluminescent assay methods |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| AU8269898A (en) | 1997-06-27 | 1999-01-19 | Regents Of The University Of California, The | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor |
| WO1999000951A1 (en) | 1997-06-30 | 1999-01-07 | Motorola Inc. | Circuit and packet switched network interconnection |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US6482923B1 (en) | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
| US6016800A (en) | 1997-10-24 | 2000-01-25 | Century; Theodore J. | Intrapulmonary aerosolizer |
| US6165783A (en) * | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| US6743427B1 (en) * | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| CN1206004C (zh) | 1997-12-11 | 2005-06-15 | 阿尔扎有限公司 | 增强透皮物剂流量的装置 |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| JP4113670B2 (ja) | 1998-06-22 | 2008-07-09 | イムノメディクス， インコーポレイテッド | プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用 |
| US6348210B1 (en) | 1998-11-13 | 2002-02-19 | Alza Corporation | Methods for transdermal drug administration |
| US6375975B1 (en) | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
| ATE300957T1 (de) | 1998-12-22 | 2005-08-15 | Genentech Inc | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
| US6284262B1 (en) | 1999-01-26 | 2001-09-04 | Virgil A. Place | Compact dosage unit for buccal administration of a pharmacologically active agent |
| US7214658B2 (en) * | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
| AU3512300A (en) | 1999-03-05 | 2000-09-21 | Epigenesis Pharmaceuticals, Inc. | Method for validating/invalidating target(s) and pathways |
| US7410941B1 (en) * | 1999-04-13 | 2008-08-12 | The Kenneth S. Warren Institute, Inc. | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin |
| ATE405636T1 (de) * | 1999-06-16 | 2008-09-15 | Boston Biomedical Res Inst | Immunologische kontrolle des beta-amyloid gehaltes in vivo |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| AU6607100A (en) | 1999-07-23 | 2001-02-13 | Regents Of The University Of California, The | Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery |
| US20020052311A1 (en) * | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| JP3589912B2 (ja) * | 1999-09-03 | 2004-11-17 | 泰久 福井 | ホスファチジルイノシトール−３，４−二リン酸を認識するモノクローナル抗体 |
| US6195605B1 (en) | 1999-09-29 | 2001-02-27 | Bmi Technologies Inc. | Impact monitor |
| US6585971B1 (en) * | 1999-11-12 | 2003-07-01 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof |
| EP2298333A3 (en) | 1999-12-20 | 2012-05-02 | Immunex Corporation | Tweak receptor |
| US6248262B1 (en) * | 2000-02-03 | 2001-06-19 | General Electric Company | Carbon-reinforced thermoplastic resin composition and articles made from same |
| JP2003531582A (ja) * | 2000-02-29 | 2003-10-28 | レキシコン・ジェネティクス・インコーポレーテッド | ヒトトランスポータータンパクおよびそれをコードするポリヌクレオチド |
| US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
| US6696274B2 (en) * | 2000-05-03 | 2004-02-24 | Supratek Pharma, Inc. | Ligand for enhancing oral and CNS delivery of biological agents |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US20030165853A1 (en) * | 2000-12-04 | 2003-09-04 | The Regents Of The University Of California Office Of Technology Transfer | Antisense imaging of gene expression of the brain in vivo |
| US6908902B2 (en) * | 2001-02-02 | 2005-06-21 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| PL362411A1 (en) * | 2001-02-06 | 2004-11-02 | Merck Patent Gmbh | Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity |
| US8163289B2 (en) | 2001-03-09 | 2012-04-24 | Iterative Therapeutics, Inc. | Methods and compositions involving polymeric immunoglobulin fusion proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| ES2300439T3 (es) | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US20030129186A1 (en) * | 2001-07-25 | 2003-07-10 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| EP1944040B1 (en) * | 2001-08-17 | 2012-08-01 | Washington University | Assay method for Alzheimer's disease |
| US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| CA2463473A1 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Targeted therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US7053202B2 (en) * | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| EP1514106A4 (en) | 2002-05-29 | 2007-05-09 | Zystor Therapeutics Inc | TARGETED THERAPEUTIC PROTEINS |
| DE60305919T2 (de) | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US20050142141A1 (en) | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| US20040102369A1 (en) * | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
| EP1592440A4 (en) * | 2003-02-10 | 2007-07-11 | Elan Pharm Inc | IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME |
| CN110496230A (zh) | 2003-02-11 | 2019-11-26 | 夏尔人类遗传性治疗公司 | 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗 |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| AU2004252171B2 (en) | 2003-06-27 | 2011-04-21 | Biogen Ma Inc. | Modified binding molecules comprising connecting peptides |
| US7112299B2 (en) | 2003-07-09 | 2006-09-26 | Michael Merrick | Systems and methods for fabricating composite fiberglass laminate articles |
| US7294704B2 (en) * | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
| EP1548031A1 (en) * | 2003-12-22 | 2005-06-29 | Dubai Genetics FZ-LLC | Nature-identical erythropoietin |
| EP2532742B1 (en) * | 2004-01-30 | 2018-08-08 | Shire Pharmaceuticals Ireland Limited | Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject |
| CN1922313B (zh) | 2004-02-10 | 2011-10-26 | 生物马林医药公司 | 酸性α-糖苷酶及其片段 |
| AU2005211890B2 (en) * | 2004-02-12 | 2011-07-28 | Merck Patent Gmbh | Highly concentrated liquid formulations of anti-EGFR antibodies |
| US7939490B2 (en) * | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| WO2006081171A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| JP5137814B2 (ja) | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート |
| EP1897940A4 (en) | 2005-05-02 | 2009-04-15 | Toray Industries | COMPOSITION AND METHOD FOR DIAGNOSIS OF CREAM CANCER AND METASTASIS OF CREAM CANCER |
| EA014513B1 (ru) | 2005-08-03 | 2010-12-30 | Иммьюноджен, Инк. | Композиция иммуноконъюгата |
| US8124076B2 (en) | 2005-08-18 | 2012-02-28 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against β-amyloid peptide |
| WO2007044468A2 (en) | 2005-10-05 | 2007-04-19 | The Cbr Institute For Biomedical Research, Inc. | Method to treat flavivirus infection with sirna |
| US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| CN101292036B (zh) | 2005-10-21 | 2016-04-13 | 弗·哈夫曼-拉罗切有限公司 | 用于重组表达多肽的方法 |
| WO2007091250A2 (en) | 2006-02-06 | 2007-08-16 | The Medical Research And Infrastructure Fund Of The Tel-Aviv Sourasky Medical Center | Enzyme replacement therapy for treating lysosomal storage diseases |
| IL193282A (en) | 2006-02-06 | 2013-04-30 | Yeda Res & Dev | Chimeric protein of therapeutic enzyme and granulocyte-stimulating factor for treatment of lysosomal storage diseases |
| US7981417B2 (en) | 2006-06-07 | 2011-07-19 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting anti-bodies |
| US7744879B2 (en) | 2006-06-07 | 2010-06-29 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| US8497246B2 (en) * | 2006-08-18 | 2013-07-30 | Armagen Technologies, Inc. | Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions |
| US9388425B2 (en) | 2006-10-20 | 2016-07-12 | Trustees Of Boston University | Tunable genetic switch for regulating gene expression |
| JP2010510794A (ja) * | 2006-11-28 | 2010-04-08 | ハナル ファーマシューティカル カンパニー リミテッド | 修飾型エリスロポエチンポリペプチド及びこの治療用用途 |
| WO2008151841A2 (en) * | 2007-06-15 | 2008-12-18 | University Of Zurich | Treatment for alzheimer' s disease |
| EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| WO2009070597A2 (en) | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
| HRP20170698T1 (hr) | 2008-05-07 | 2017-09-22 | Biomarin Pharmaceutical Inc. | Lizosomski usmjereni peptidi i njihove uporabe |
| WO2010003101A2 (en) | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | Il6 immunotherapeutics |
| US20100077498A1 (en) * | 2008-09-11 | 2010-03-25 | Pardridge William M | Compositions and methods for blood-brain barrier delivery in the mouse |
| US20100098693A1 (en) * | 2008-10-07 | 2010-04-22 | Pardridge William M | Compositions and methods for blood-brain barrier delivery of organophosphatases |
| CN102300987A (zh) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | 膜型-1基质金属蛋白抑制剂及其用途 |
| JP5873003B2 (ja) | 2009-03-18 | 2016-03-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法 |
| JP2012529432A (ja) | 2009-06-05 | 2012-11-22 | リンク・メディスン・コーポレーション | アミノピロリジノン誘導体及びその使用 |
| CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| MX2013000324A (es) | 2010-06-25 | 2013-02-01 | Shire Human Genetic Therapies | Tratamiento del sindrome de sanfilippo tipo b. |
| BR112012033197A2 (pt) | 2010-06-25 | 2017-06-06 | Shire Human Genetic Therapies | métodos e composições para liberação de cns de n-sulfatase de heparano. |
| PT2588130T (pt) | 2010-06-25 | 2016-11-25 | Shire Human Genetic Therapies | Entrega de agentes terapêuticos no cns |
| UA115649C2 (uk) | 2010-06-25 | 2017-12-11 | Шае Хюмен Дженетік Терапіс, Інк. | Способи та композиції для доставки до цнс ідуронат-2-сульфатази |
| BR112013013083A2 (pt) | 2010-11-30 | 2016-12-13 | Genentech Inc | métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo |
| US9206401B2 (en) | 2010-12-22 | 2015-12-08 | Fondazione Telethon | Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| US20130039888A1 (en) | 2011-06-08 | 2013-02-14 | Nationwide Children's Hospital Inc. | Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
| WO2012177997A1 (en) | 2011-06-22 | 2012-12-27 | The General Hospital Corporation | Treatment of proteinopathies |
| US8859256B2 (en) | 2011-10-05 | 2014-10-14 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| RU2014117291A (ru) | 2011-10-12 | 2015-11-20 | Синаджева Биофарма Корп. | Рекомбинантный человеческий белок naglu и его применение |
| US8486399B2 (en) * | 2011-12-02 | 2013-07-16 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| WO2013181454A1 (en) | 2012-05-30 | 2013-12-05 | Biostrategies LC | Plant lectins as carriers of associated drug substances into animal and human cells |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| US9540442B2 (en) | 2012-08-02 | 2017-01-10 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
| EP2910632B1 (en) | 2012-10-19 | 2017-07-05 | Tokushima University | Highly functional enzyme having modified substrate specificity of human beta-hexosaminidase b and exhibiting protease resistance |
| JP6083219B2 (ja) | 2012-12-06 | 2017-02-22 | 富士通セミコンダクター株式会社 | プラズマフラッドガン及びイオン注入装置 |
| US20140354655A1 (en) | 2013-06-04 | 2014-12-04 | Qualcomm Mems Technologies, Inc. | Reducing floating node leakage current with a feedback transistor |
| US10906981B2 (en) | 2013-07-19 | 2021-02-02 | The Regents Of The University Of California | Compositions and methods related to structures that cross the blood brain barrier |
| WO2015012944A1 (en) | 2013-07-22 | 2015-01-29 | Armagen Technologies, Inc | Methods and compositions for increasing enzyme activity in the cns |
| PL3119892T3 (pl) | 2014-03-17 | 2021-11-29 | The Hospital For Sick Children | Warianty białka beta-heksozaminidazy oraz związane z nimi sposoby do leczenia gangliozydoz gm2 |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| TWI761413B (zh) | 2016-12-26 | 2022-04-21 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| WO2018124277A1 (ja) | 2016-12-28 | 2018-07-05 | Ｊｃｒファーマ株式会社 | 凍結乾燥製剤 |
| JP7532338B2 (ja) | 2018-08-07 | 2024-08-13 | アーマジェン・インコーポレイテッド | ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル－タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物 |
| WO2020132452A1 (en) | 2018-12-20 | 2020-06-25 | Shire Human Genetic Therapies, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
| US20210403584A1 (en) | 2019-01-08 | 2021-12-30 | Armagen, Inc. | Methods and compositions for increasing galactosidase beta-1 activity in the cns |
-
2010
- 2010-10-08 JP JP2012533375A patent/JP2013507131A/ja not_active Withdrawn
- 2010-10-08 EP EP23183395.5A patent/EP4273164A3/en active Pending
- 2010-10-08 PT PT10822810T patent/PT2485761T/pt unknown
- 2010-10-08 HR HRP20190690TT patent/HRP20190690T1/hr unknown
- 2010-10-08 HU HUE10822810 patent/HUE044865T2/hu unknown
- 2010-10-08 EP EP19150184.0A patent/EP3533467B1/en active Active
- 2010-10-08 DK DK10822810.7T patent/DK2485761T3/da active
- 2010-10-08 US US12/901,481 patent/US8834874B2/en active Active
- 2010-10-08 PL PL10822810T patent/PL2485761T3/pl unknown
- 2010-10-08 ES ES10822810T patent/ES2725200T3/es active Active
- 2010-10-08 EP EP10822810.7A patent/EP2485761B1/en active Active
- 2010-10-08 SI SI201031879T patent/SI2485761T1/sl unknown
- 2010-10-08 WO PCT/US2010/052113 patent/WO2011044542A1/en not_active Ceased
-
2014
- 2014-06-16 US US14/305,402 patent/US10011651B2/en active Active
-
2016
- 2016-01-28 JP JP2016014716A patent/JP2016155805A/ja active Pending
-
2018
- 2018-05-08 JP JP2018089998A patent/JP2018154629A/ja active Pending
- 2018-05-17 US US15/982,990 patent/US11028156B2/en active Active
-
2020
- 2020-10-01 JP JP2020167101A patent/JP2021008488A/ja active Pending
-
2021
- 2021-04-30 US US17/246,288 patent/US12043661B2/en active Active
-
2022
- 2022-12-22 JP JP2022205808A patent/JP2023033321A/ja active Pending
-
2024
- 2024-06-11 US US18/740,035 patent/US20240327507A1/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| JPN6014043802; Ｂｉｏｃｏｎｊｕｇａｔｅ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．１９，Ｎｏ．７, 2008, ｐ．１３２７-１３３８ * |
| JPN6014043804; Ｂｉｏｔｅｃｈｎｏｌｏｇｙ ａｎｄ Ｂｉｏｅｎｇｉｎｅｅｒｉｎｇ Ｖｏｌ．９９，Ｎｏ．２, 2008, ｐ．４７５-４８４ * |
| JPN6014043806; Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．ＵＳＡ Ｖｏｌ．９０, 1993, ｐｐ．１１８３０-１１８３４ * |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016155805A (ja) * | 2009-10-09 | 2016-09-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| JP2016525545A (ja) * | 2013-07-22 | 2016-08-25 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2024012225A (ja) * | 2013-07-22 | 2024-01-26 | アーマジェン・インコーポレイテッド | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2020171284A (ja) * | 2013-07-22 | 2020-10-22 | アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2021180658A (ja) * | 2013-07-22 | 2021-11-25 | アーマジェン・インコーポレイテッドArmagen, Inc. | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| WO2015098989A1 (ja) | 2013-12-25 | 2015-07-02 | Ｊｃｒファーマ株式会社 | 血液脳関門を通過する新規抗トランスフェリン受容体抗体 |
| JPWO2015098989A1 (ja) * | 2013-12-25 | 2017-03-23 | Ｊｃｒファーマ株式会社 | 血液脳関門を通過する新規抗トランスフェリン受容体抗体 |
| US9994641B2 (en) | 2013-12-25 | 2018-06-12 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody that passes through blood-brain barrier |
| EP3450557A1 (en) | 2013-12-25 | 2019-03-06 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
| JP7232889B2 (ja) | 2016-08-25 | 2023-03-03 | Ｊｃｒファーマ株式会社 | 抗体融合蛋白質の製造方法 |
| JP2022028959A (ja) * | 2016-08-25 | 2022-02-16 | Ｊｃｒファーマ株式会社 | 抗体融合蛋白質の製造方法 |
| US11512135B2 (en) | 2016-08-25 | 2022-11-29 | Jcr Pharmaceuticals Co., Ltd. | Method for producing antibody fusion protein |
| WO2018038243A1 (ja) * | 2016-08-25 | 2018-03-01 | Ｊｃｒファーマ株式会社 | 抗体融合蛋白質の製造方法 |
| JP2021533167A (ja) * | 2018-08-07 | 2021-12-02 | アーマジェン・インコーポレイテッドArmagen, Inc. | ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル−タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物 |
| JP7532338B2 (ja) | 2018-08-07 | 2024-08-13 | アーマジェン・インコーポレイテッド | ヘキソサミニダーゼａ、酸スフィンゴミエリナーゼおよびパルミトイル－タンパク質チオエステラーゼ１のｃｎｓにおける活性を増加させるための方法および組成物 |
| JP2022512575A (ja) * | 2018-10-26 | 2022-02-07 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | Ｉｄｓを含む融合タンパク質及びその使用 |
| JP7206524B2 (ja) | 2018-10-26 | 2023-01-18 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | Ｉｄｓを含む融合タンパク質及びその使用 |
| US12098209B2 (en) | 2018-10-26 | 2024-09-24 | Mogam Institute For Biomedical Research | Fusion protein comprising IDS and use thereof |
| JP2022526799A (ja) * | 2019-04-03 | 2022-05-26 | デナリ セラピューティクス インコーポレイテッド | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
| JP7715635B2 (ja) | 2019-04-03 | 2025-07-30 | デナリ セラピューティクス インコーポレイテッド | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
| JP2024532176A (ja) * | 2021-08-18 | 2024-09-05 | ジョイント－ストック カンパニー “ジェネリウム” | 療法酵素のターゲティング化送達 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018154629A (ja) | 2018-10-04 |
| US20190185551A2 (en) | 2019-06-20 |
| US20240327507A1 (en) | 2024-10-03 |
| US11028156B2 (en) | 2021-06-08 |
| PL2485761T3 (pl) | 2019-10-31 |
| US12043661B2 (en) | 2024-07-23 |
| EP4273164A3 (en) | 2024-01-24 |
| WO2011044542A1 (en) | 2011-04-14 |
| US20150004160A1 (en) | 2015-01-01 |
| EP2485761A1 (en) | 2012-08-15 |
| EP2485761A4 (en) | 2013-04-03 |
| HRP20190690T1 (hr) | 2019-06-28 |
| EP3533467A2 (en) | 2019-09-04 |
| EP2485761B1 (en) | 2019-02-27 |
| EP3533467A3 (en) | 2020-01-15 |
| HUE044865T2 (hu) | 2019-11-28 |
| SI2485761T1 (sl) | 2019-05-31 |
| US20210253681A1 (en) | 2021-08-19 |
| US8834874B2 (en) | 2014-09-16 |
| JP2021008488A (ja) | 2021-01-28 |
| JP2016155805A (ja) | 2016-09-01 |
| US20180251535A1 (en) | 2018-09-06 |
| DK2485761T3 (da) | 2019-05-06 |
| EP3533467B1 (en) | 2023-07-26 |
| EP4273164A2 (en) | 2023-11-08 |
| ES2725200T3 (es) | 2019-09-20 |
| PT2485761T (pt) | 2019-05-30 |
| JP2023033321A (ja) | 2023-03-10 |
| US20110110935A1 (en) | 2011-05-12 |
| US10011651B2 (en) | 2018-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240327507A1 (en) | Methods and compositions for increasing iduronate 2-sulfate activity in the cns | |
| US20230279156A1 (en) | Methods and compositions for increasing alpha-l-iduronidase activity in the cns | |
| JP6914392B2 (ja) | Ｃｎｓにおける酵素活性を増大するための方法および組成物 | |
| US20240409650A1 (en) | Methods and compositions for increasing n-acetylglucosaminidase activity in the cns | |
| AU2012346448B2 (en) | Methods and compositions for increasing arylsulfatase A activity in the CNS | |
| US20250179201A1 (en) | Methods and compositions for increasing galactosidase beta-1 activity in the cns | |
| HK40013772A (en) | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130605 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141021 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150220 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150317 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150420 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150929 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160128 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160404 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20160610 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170221 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170321 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170421 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170522 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20170731 |